Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study

Author:

Wen Meng-JungORCID,Hsu Han-Lin,Chang Chia-Lun,Wang Jou-Han,Kuo Chun-Nan,Hsin Yen-Chun,Chang Elizabeth H.ORCID

Abstract

Background and objective Patients with cancer taking oral antineoplastic medications may encounter problems including suboptimal adherence as well as physical and psychological disease burden. Despite increase in the use of oncology pharmacy services, there are wide variations between healthcare professionals and patient perceptions of patients’ medication experiences. The objective of the study was to explore the medication experience of taking oral targeted therapy in patients with advanced non-small cell lung cancer (NSCLC). Method We purposively sampled advanced stage (stage III or IV) NSCLC patients taking epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in a medical center in Taiwan. Face-to-face interviews using semi-structured interview guides were conducted. Interviews were transcribed verbatim and thematic analysis was applied. A phenomenological methodology was adopted to explore the underlying meaning of patients’ lived experience. Results A total of 19 participants with a mean age of 68.2 years were interviewed. The duration of EGFR-TKIs use ranged from 2 weeks to 5 years. When first learned about the unexpected yet ‘treatable’ cancer, participants expressed strong emotional responses based on their intrinsic beliefs of the terminal disease and therapy. They walked along an unfamiliar trail while confronting physical and psychological challenges and made compromises to treatment. Gaining experiences from cancer journey, patients with cancer continuously seek the ultimate goals–‘return to normal’. Conclusions This study also revealed medication experiences of participants’ journey from seeking information in the initial phase and living with cancer, to taking back control of their own lives. Healthcare professionals could better empathize with patients’ loss of control and understand their perspectives when making clinical decisions. These findings can guide interdisciplinary teams to integrate patients’ beliefs and conduct pre-screening assessments of health literacy levels to tailor communication. Subsequent interventions should be developed to identify barriers to medication self-management and empower patients by building social networks.

Funder

Ministry of Science and Technology, Taiwan

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference34 articles.

1. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study;KE Skinner;J Med Econ,2018

2. Cancer statistics, 2022;RL Siegel;CA: a cancer journal for clinicians,2022

3. Midthun D. Overview of the initial treatment and prognosis of lung cancer: UpToDate; 2021 [updated Feb 07, 2020. https://www.uptodate.com/contents/overview-of-the-initial-treatment-and-prognosis-of-lung-cancer?search=lung%20cancer&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#H4.

4. Trends in Lung Cancer Incidence Rates by Histological Type in 1975–2008: A Population-Based Study in Osaka, Japan;FL Kinoshita;J Epidemiol,2016

5. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature;D Eek;Patient Prefer Adherence,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3